Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No.

Abstract excerpt

Patients who benefit the most from combinations of an androgen receptor pathway inhibitor and a PARP inhibitor are those with a BRCA mutation, but there are certainly patients without BRCA mutations who will benefit from this treatment strategy.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Androgen Receptor Antagonists
• Share to Antineoplastic Combined Chemotherapy Protocols
• Share to BRCA2 Protein